stars 1 stars 2 stars 3

Peptinov is a biotechonology company based in Cochin Hospital (Paris, France) and founded by Prof. Jean-François Zagury to develop innovative peptide-based immunotherapies to treat chronic inflammatory diseases. Peptinov’s strategy is to induce the production of antibodies targeting self-proteins directly by the organism of the patient, through immunizations against carefully selected, highly immunogenic peptide sequences. Peptinov’s high potential R&D platform uses the tools of bioinformatics and molecular modelling to design these peptide sequences. This platform is potentially applicable to any crystallized protein and can quickly generate peptide candidates. Peptinov’s value proposition is built on its unique capability to develop anti-self proteins products in the current pharmaceutical markets. Peptinov's most advanced product targets IL-6, a central pro-inflammatory cytokine involved in the pathogenesis of several diseases. Peptinov's anti-IL-6 immunotherapy is now in phase 1 clinical development. Video of Peptinov's approach: https://youtu.be/8j0GvgqPjxQ

PEPTINOV Questions

The PEPTINOV annual revenue was $608000 in 2026.

René Azoulai is the CEO of PEPTINOV.

9 people are employed at PEPTINOV.

PEPTINOV is based in Paris, Ile de France.

The NAICS codes for PEPTINOV are [5417, 541713, 541, 54171, 54].

The SIC codes for PEPTINOV are [873, 87].

Top PEPTINOV Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users